We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Sandra and Edward Meyer Cancer Center

Warning message

The subscription service is currently unavailable. Please try again later.

You are here


Peter Martin, M.D., Talks Trial of Oral Azacitidine Plus R-CHOP in High Risk DLBCL

Friday, January 5, 2018

Peter Martin, M.D., discusses a trial of the combination of oral azacitidine (CC-486) and R-CHOP in diffuse large B-cell lymphoma (DLBCL). This was a phase I, open-label, multicenter trial of oral azacitidine plus R-CHOP in patients with high-risk, previously untreated DLBCL, grade 3B follicular lymphoma, or transformed lymphoma.